A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, with Functional Constipation (FC) with a 24-week Open-label Treatment Extension

There are no current, approved therapies to treat children ages 2 to 5 with pediatric functional constipation (PFC). Therefore, we aim to evaluate whether linaclotide can be an effective and safe therapy for children with functional constipation (FC) in this age group.